Camp4 Therapeutics Corp (CAMP): Operating Cash Flow
-$29.55M
Year ended 2025-12-31
-$28.59M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$29.55M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$45.56M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$44.16M | n/a | 2025-03-27, From 2023-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | -$29.55M | n/m |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | -$12.01M | n/m |
| CervoMed Inc. (CRVO) | 2025-12-31 | -$23.45M | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | -$2.29M | n/m |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $148.3K | n/m |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | -$133.28M | n/m |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | -$8.34M | n/m |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | -$73.94M | n/m |
Compare CAMP, MRKR, CRVO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗